Therapeutics Information for Providers
This page is for healthcare providers. Looking for information about what to do if you feel sick?
Latest Updates
NCDHHS greatly appreciates all N.C. providers’ assistance in reconciling the data for U.S. government-procured COVID-19 therapeutics. Reporting for monoclonal antibodies is now closed. Reporting for oral antivirals remains open for partners and federal entities who are still dispensing U.S. government-procured Lagevrio or Paxlovid.
Sites are encouraged to voluntarily opt in to the ASPR Treatments Locator for commercially available treatments by filling out the web form or reporting in HPOP at least every 60 days to help patients and healthcare providers find these products quickly in their communities.
Product Summaries
| Brand Name | Also Known As | Approved or Authorized Indication | Prioritization | Fact Sheets or Package Inserts | Site Finder | Patient Assistance Program |
|---|---|---|---|---|---|---|
| Paxlovid | Nirmatrelvir / Ritonavir, Pfizer | Authorized for treatment of mild-to-moderate COVID-19 in patients ages 12 and older who are at risk for progressing to severe COVID-19 and/or hospitalization within 5 days of symptoms (FDA approved for ages 18 and older) | First line treatment option | Paxlovid Prescribing Information | HHS/ASPR Find COVID-19 Medications | |
| Lagevrio | Molnupiravir | Authorized for treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization within 5 days of symptoms | Alternative oral antiviral for patients for whom neither Paxlovid nor Veklury are clinically appropriate or feasible | HHS/ASPR Find COVID-19 Medications | MerckHelps | |
| Veklury | Remdesivir | Approved for treatment of mild to moderate COVID-19 in high-risk patients ages 28 days and older weighing at least 3 kg within 7 days of symptoms | First line treatment where Paxlovid is not appropriate | Veklury Prescribing Information | HHS/ASPR Find COVID-19 Medications | Gilead’s Advancing Access |
Paxlovid Clinical Resources
More Provider Resources
Helpful Links
- NIH Outpatient COVID-19 Treatment Guidelines
- CDC COVID-19 Treatment Clinical Care for Outpatients
- CDC Clinical Course: Progression, Management and Treatment
- Subscribe to NCDHHS Therapeutics Provider Communications
- Recissions of Statewide Standing Orders for mAbs Administration
Need Help?
Contact the Testing and Therapeutics team at covid19testingandtreatments@dhhs.nc.gov.
Recent Updates
As the U.S. Department of Health and Human Services (HHS) is no longer distributing therapeutics, except to certain federal entities, all providers that received HHS-procured COVID-therapeutics are asked to finalize their reporting data in HPOP.
All delivered products must be accounted for as administered, transferred, wasted, returned, or on-hand inventory by June 14, 2024. Get more information and guidance for reporting in HPOP in this email distributed to all therapeutics providers on June 3.
State Health Director and Chief Medical Officer Dr. Tilson has issued an updated COVID-19 Treatment Provider Memo highlighting two important messages for all NC clinicians:
- As of March 9, 2024, EUA-labeled Paxlovid is no longer authorized for emergency use, and only NDA-labeled Paxlovid can be dispensed moving forward.
- Despite this change, all patients, regardless of insurance status, can continue to have access to Paxlovid at little to no cost through the PAXCESS Patient Support Program.
Read the memo for more information on how to provide low-cost COVID-19 treatment to your patients.
Ordering for government-distributed oral antivirals closed Dec. 15, 2023. Paxlovid and Lagevrio are available commercially through wholesalers.
Using/Returning USG-distributed Product
- Paxlovid: Providers are encouraged to follow the Paxlovid returns process to return excess product expiring December 2023 or later. Return by Jan. 31, 2024, to help USG earn a credit for use in the USG Patient Assistance Program. The program will provide free, NDA-labeled Paxlovid for Medicare, Medicaid and uninsured patients.
- Lagevrio: Use until depleted or expired, whichever comes first.
More information: COVID-19 treatments transition operational guide
COVID-19 oral antiviral treatments, Paxlovid and Lagevrio, will be available for commercial purchase on Nov. 1, 2023. The current government distribution process will continue beyond Nov. 1 for both products to allow the commercial pipeline to mature and ensure there are no gaps in access. To prepare for the transition of these products from a government-managed distribution process to traditional commercial distribution, the U.S. Department of Health and Human Services has prepared a COVID-19 treatments transition operational guide with target dates and detailed information for each step in the transition process.
Staying up to date with vaccines and timely access to treatment are the best ways to reduce hospitalization and death due to COVID-19. This memo provides updated guidance for healthcare providers about outpatient treatment of COVID-19 and includes key treatment messages, information about product accessibility, and an overview of treatment options. Read the memo.
Have questions? We're here to help.
Contact the Testing and Therapeutics team at covid19testingandtreatments@dhhs.nc.gov.